Research programme: beta catenin inhibitors - Prolexys

Drug Profile

Research programme: beta catenin inhibitors - Prolexys

Alternative Names: Pair 4 compound series; PRLX 43318 compound series; PRLX 8025; PRLX2113; PRXL 2113

Latest Information Update: 23 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prolexys Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Beta catenin inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 23 Aug 2006 This programme is still in active development for Colorectal cancer
  • 25 Feb 2005 Preclinical trials in Colorectal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top